Cabiralizumab

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameCabiralizumab
Drug Alias NameBMS-986227ONO-4687FPA-008
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionColony stimulating factor 1 receptor inhibitors
TargetsColony stimulating factor 1 receptor
Therapy Area/IndicationsSolid tumoursArthritis, RheumatoidCarcinoma, Non-Small-Cell Lung +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[15] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesFive Prime Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyWashington University School Of MedicineUniversity Of Michigan Rogel Cancer Center
Inactive CompaniesFive Prime Therapeutics Inc
Active IndicationsPancreatic NeoplasmsTriple Negative Breast NeoplasmsLymphoma, T-Cell, Peripheral
Inactive IndicationsSolid tumoursArthritis, RheumatoidCarcinoma, Non-Small-Cell Lung +[10] 

Other Information

ATC CodeN/A
Related LinksN/A